Our History
Diag2Tec was founded in June 2015 as a spin-off from leading academic and hospital research teams in Montpellier: CNRS UMR9002 from the Institute of Human Genetics, and the “Monitoring Innovative Therapies” team from Montpellier University Hospital (CHU). Building on the pioneering work of Prof. Bernard Klein and Prof. Jérôme Moreaux, the company emerged from a highly integrated and cooperative hospital-academic environment dedicated to hematologic malignancies, at the interface of fundamental research, clinical investigation, and translational innovation.
Diag2Tec has grown within Montpellier’s dynamic life sciences ecosystem, benefiting from strong regional Occitanie and national support (ADOCC, Montpellier Métropole, Eurobiomed, Bpifrance, CNRS Innovation). Initially incubated at the Montpellier BIC, the company evolved in an innovation-driven environment that fostered entrepreneurship and technology transfer. In 2017 Diag2Tec established its laboratories within the Hematology Department at Saint-Éloi Hospital (CHU Montpellier), enabling close interaction with clinicians, direct access to patient samples, and seamless integration of translational research.
Since April 2025, Diag2Tec has been located within the CRIBS at the Site Unique de Biologie (SUB) of the CHU Montpellier, a state-of-the-art infrastructure designed to centralize high-level biological expertise, promotes deep interaction with Montpellier CHU’s capabilities and accelerate research and innovation. The unique Montpellier’s environment promotes synergies between clinicians, researchers, and industry partners, fostering collaborative projects and public–private partnerships to advance diagnostics, therapeutic strategies, and precision medicine.
